Making Oligonucleotides Better Biopharmaceuticals by Steric Protection

通过空间保护使寡核苷酸成为更好的生物制药

基本信息

批准号：
10259829
负责人：
Ke Zhang
金额：
$ 31.15万
依托单位：
NORTHEASTERN UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-01 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10259829
关键词：
Acute Address Animals Antibodies Antisense DNA Benign Binding Biodistribution Biological Biological Products Blood Circulation Blood Coagulation Disorders Bypass Catalytic RNA Cations Cells Characteristics Chemical Structure Chemicals Chronic Complementary DNA Complex Congestive DNA DNA Binding DNA Probes DNA Sequence Data Deoxyribonucleases Development Disease Drug resistance Electrostatics Environment Enzyme Stability Exhibits Face Gene Therapy Agent Genes Genetic Genetic Diseases Goals Half-Life Immune response Immune system Immunization In Vitro Insulin Intracellular Transport Investigation Kidney Kinetics Liposomes Liver Malignant Neoplasms MicroRNAs Modality Modeling Modification Molecular Neurodegenerative Disorders Nucleic Acids Oligonucleotides Outcome Study Pattern Pattern recognition receptor Peptides Permeability Pharmaceutical Preparations Polymers Property Proteins Reticuloendothelial System Safety Serum Serum Proteins Side Small Interfering RNA Specificity Structure System TLR9 gene Therapeutic Therapeutic Agents Thermodynamics Thrombin Toxic effect Vertebral column Work aptamer base biological systems biomaterial compatibility cancer cell density design efficacy study ethylene glycol gene therapy gene therapy clinical trial immunogenic immunogenicity improved in vivo insight interest knock-down mouse model nanoparticle novel nuclease nucleic acid delivery pathogen pharmacokinetics and pharmacodynamics preservation prevent protein expression refractory cancer side effect single molecule stem tumor uptake

项目摘要

Project Summary/Abstract Significant interests exist for using oligonucleotides as therapeutic agents, which face several biopharmaceutical difficulties, including stability and delivery issues, and sequence- and/or chemical structure-specific, non-hybridization activities, such as coagulopathies and stimulation of the immune system. These difficulties have been in part overcome by chemical modification of the oligonucleotide backbone or by using delivery systems (oftentimes polycationic structures), which enhance nuclease stability and improve delivery efficiency. However, these approaches either give rise to new challenges (e.g. toxicity and immunogenicity), or cannot adequately address all of the negative aspects. Therefore, a system that can improve nuclease stability, preserve target-binding capability, minimize all off-target effects, and improve biodistribution is still very much sought after. Our preliminary studies have demonstrated that “compaction” of DNA can be achieved by inserting it into a high-density brush polymer environment, which enables the DNA to bind selectively to a complementary DNA strand, while access by various proteins is limited. The binding of DNA with proteins such as nucleases, toll-like receptor 9, and thrombin is generally the first step to non-hybridization side effects. Therefore, the brush polymer- DNA conjugates should bypass many of the side effects of oligonucleotides and has the potential to be applied to essentially all forms of oligonucleotides, i.e. antisense DNA, siRNA, microRNA, aptamers, ribozymes, etc., to improve their biopharmaceutical characteristics. The outcome of this study would be a new class of biocompatible and non-immunostimulatory oligonucleotide-based gene therapy agents, and a fundamental understanding of how its molecular parameters can impact its in vivo and in vitro properties.

项目概要/摘要使用寡核苷酸作为治疗剂存在重大兴趣，这面临着几个问题生物制药困难，包括稳定性和递送问题，以及序列和/或化学问题结构特异性、非杂交活性，例如凝血病和免疫系统刺激这些困难已通过寡核苷酸的化学修饰部分克服。主链或通过使用增强核酸酶的递送系统（通常是聚阳离子结构）然而，这些方法要么带来了新的挑战。（例如毒性和免疫原性），或无法充分解决所有负面方面。系统可以提高核酸酶稳定性，保留靶点结合能力，最大限度地减少所有脱靶我们的初步研究表明，影响和改善生物分布仍然非常受追捧。 DNA 的“压缩”可以通过将其插入高密度刷状聚合物来证明环境，使 DNA 能够选择性地结合到互补的 DNA 链上，同时访问 DNA 与核酸酶、Toll 样受体 9 等蛋白质的结合受到限制。而凝血酶一般是第一步，无杂交副作用，因此刷多聚体。 DNA 缀合物应该绕过寡核苷酸的许多副作用，并且有可能被适用于基本上所有形式的寡核苷酸，即反义 DNA、siRNA、microRNA、适体、核酶等，以改善其生物制药特性。新型生物相容性和非免疫刺激性寡核苷酸基因治疗剂，以及对分子参数如何影响体内和体外的基本了解特性。